Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [ACTIVE] · [HEALTH]
2 clusters · 12 sources · 16 days · First seen · Last updated
Clinical developments in obesity and diabetes medications
Overview
Pharmaceutical developments regarding experimental treatments for obesity and type 2 diabetes have shown positive results in Phase II clinical trials.
In late September 2026, Roche and Genentech reported successful Phase II results for enicepatide, a once-weekly dual GLP-1/GIP receptor agonist. At a 24 mg dose, participants saw a mean weight loss of 15.5% over 48 weeks and significant improvements in glycemic control. Roche intends to move the drug into Phase III studies.
By early October 2026, Zealand Pharma reported that its amylin-mimicking therapy, petrelintide, met primary endpoints in a Phase 2 study. Patients receiving once-weekly doses experienced weight loss between 7.4% and 9.2% over 28 weeks, alongside improvements in HbA1c levels. Zealand Pharma is developing this therapy in collaboration with Roche, and the two companies have transitioned to late-stage testing involving approximately 7,000 participants.
Entities
Roche · Petrelintide · Enicepatide · Genentech · Zealand Pharma
Timeline
-
[HEALTH] 3 sourcesZealand Pharma reports positive Phase 2 results for obesity drug petrelintide
Zealand Pharma's Phase 2 trial of petrelintide showed weight loss of up to 9.2% in adults with obesity and type 2 diabetes, meeting its primary endpoint alongside improved blood sugar control.
-
[HEALTH] 9 sourcesRoche reports positive Phase II results for obesity and diabetes drug enicepatide
Roche's experimental drug enicepatide showed significant success in Phase II trials, reducing average weight by 15.5% and substantially lowering HbA1c levels in adults with type 2 diabetes.
Sources
ad-hoc-news.de · boerse-social.com · click.ro · doctorulzilei.ro · finanzen.at · finanznachrichten.de · immedicohospitalario.es · it-boltwise.de · mugglehead.com · srnnews.com · stocktitan.net · zmescience.com